PetVivo Holdings, Inc. (OTCQX: PETV), a biomedical device company known for its veterinary medical innovations, has entered a distribution agreement with Nupsala Limited to introduce its flagship product, Spryng® with OsteoCushion® technology, to the United Kingdom market. This move, effective September 1, 2025, aims to broaden the reach of Spryng®, a treatment designed to address joint pain and mobility issues in companion animals and horses.
PetVivo Animal Health, a wholly-owned subsidiary of PetVivo Holdings, has developed Spryng®, an intra-articular injectable device that consists of sterilized extracellular matrix microparticles. These microparticles are engineered to integrate with the synovial lining of animal joints, promoting the restoration of joint mechanics. This pioneering technology helps manage noninfectious sources of joint pain such as joint instability, degenerative joint disease, and osteoarthritis in dogs, cats, and horses. Unlike many treatments, Spryng® works without pharmacologic or metabolic action, acting instead as a bio-integrative scaffold that mimics natural cartilage properties to provide long-lasting joint support.
Mike Eldred, a Board Director at PetVivo Holdings, highlighted the significance of this agreement, emphasizing that partnering with Nupsala, a well-regarded distributor specializing in musculoskeletal health for animals, will extend Spryng®’s availability to more veterinarians and animal owners across the UK. Eldred expressed confidence in the partnership’s ability to improve animal health and quality of life through advanced medical technology.
Nupsala Limited, based in the UK, has built a reputation in veterinary musculoskeletal care, orthobiologics, and regenerative medicine for both companion animals and horses. The company combines wholesale distribution with clinical expertise and educational initiatives to support veterinarians in diagnosing and treating osteoarthritis and related musculoskeletal conditions. Greg McGarrell, CEO of Nupsala, stated that Spryng® complements their mission by providing a novel, science-based solution to support joint function and enhance animals’ quality of life. McGarrell is optimistic about working closely with PetVivo to expand access to this important treatment throughout the UK.
Spryng® with OsteoCushion® technology is distinguished by its composition of collagen, elastin, and carbohydrate molecules that self-assemble into a pliable, shock-absorbing matrix. When injected, it conforms within the joint space to simulate the dynamics of healthy cartilage, absorbing and releasing synovial fluid to cushion and protect joints under impact. A single injection is designed to deliver long-duration benefits, with a storage shelf life of up to 26 months at room temperature, making it a practical option for veterinary care.
PetVivo Holdings’ broader strategy focuses on bringing human medical technologies adapted for animals to market more rapidly and cost-effectively. This approach has allowed the company to accelerate revenue generation by focusing on medical devices, which generally face fewer regulatory hurdles and quicker market entry compared to pharmaceuticals or biologics. The company holds a portfolio of 21 patents protecting its biomaterials and methods, underscoring its dedication to innovation in veterinary therapeutics.
In addition to Spryng®, PetVivo offers PrecisePRP™, an off-the-shelf platelet-rich plasma product, designed to further promote veterinary regenerative medicine. Both products are currently available commercially, reflecting PetVivo’s commitment to offering veterinarians practical tools for improving animal health.
The new distribution agreement with Nupsala is expected to help PetVivo capitalize on the growing demand for advanced veterinary care solutions in the UK. As pet ownership rises and owners increasingly seek high-quality treatments for chronic conditions like osteoarthritis, Spryng® presents a timely option that addresses joint pain with a unique biomaterial approach.
By working with an experienced partner like Nupsala, PetVivo aims to support veterinarians in delivering effective treatments to animals suffering from joint-related afflictions and to enhance the mobility and comfort of companion animals and horses alike.
